Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone - Abstract

Department of Radiation Oncology, McGill University Health Centre, Montreal, Canada.

 

Intermediate-risk prostate cancer has been treated in many ways; the most effective treatment is uncertain. Hypofractionated external beam radiotherapy (HyRT) is a short and convenient alternative treatment. We report our results of HyRT in intermediate-risk patients.

Eighty two patients with intermediate-risk prostate cancer were treated with 3-dimensional conformal HyRT plans to the dose of 66Gy/22 fractions prescribed at the isocenter without hormones. Intermediate-risk was defined as clinical stage T2b-T2c, or pre-treatment PSA between 10 and 20ng/mL, or Gleason Score equal 7. The planning target volume consisted of the prostate plus a uniform 7mm margin. Toxicity was prospectively graded by the Common Terminology Criteria version3. Biochemical relapse was defined as post-radiotherapy nadir PSA+2ng/mL.

With a median follow-up of 51months, 5-year actuarial biochemical recurrence free survival is 95.4%. At the last follow-up visit, grade ⩾2 late gastro-intestinal and genito-urinary toxicity rates were 2% and 7%, respectively. No patient ever developed grade 4 or 5 toxicity.

HyRT to a dose of 66Gy in 22 fractions as a single treatment modality is convenient for patients and for the health care system and appears to provide similar results to other treatment choices.

Written by:
Faria S, Pra AD, Cury F, David M, Duclos M, Freeman CR, Souhami L.   Are you the author?

Reference: Radiother Oncol. 2011 Aug 22. Epub ahead of print.
doi: 10.1016/j.radonc.2011.07.005

PubMed Abstract
PMID: 21864925

UroToday.com Prostate Cancer Section

 

 

email news signup